Antihypertensive and metabolic effects of long-term treatment with amosulalol in non-insulin dependent diabetics

Abstract

In this open study, 41 hypertensive patients with non-insulin dependent diabetes mellitus were treated with the combined alpha- and beta-adrenoceptor blocker amosulalol hydrochloride for 24 weeks, either alone or added to existing antihypertensive therapy. The effects on blood pressure, glucose and lipid metabolism were examined. Daily administration of 20 to 60 mg amosulalol caused a significant reduction in both systolic and diastolic blood pressure within 2 weeks. This effect was stable, lasting for the entire trial period. The mean systolic and diastolic blood pressure decreased from 174 +/- 13/92 +/- 9 mmHg at the beginning to 148 +/- 16/80 +/- 11 mmHg at the end of the trial. Heart rate was not affected. Plasma glucose and haemoglobin Alc levels showed a tendency to decrease without any statistical significance. Total and HDL-cholesterol and triglyceride levels also remained unchanged. Although 3 patients had complained of dizziness, all were easily manageable. The results indicate that amosulalol is effective in the treatment of hypertension in non-insulin dependent diabetics and does not affect glucose and lipid metabolism.

Drug Repurposing using consilience of Knowledge Graph Completion methods

“…ADRB1 inhibition mediates adrenaline’s effect on the heart, resulting in concomitant decreased blood pressure and cardiac output (35). As sotalol and amosulalol both directly block ADRB1, a protein and gene associated with hypertension, and amosulalol has anti-hypertensive effects, it is reasonable that sotalol also has anti-hypertensive effects (36; 37).…”